EL7.AI
Mergers & AcquisitionsMediumUpdated×2•Originally published 8 October 2026•Updated 8 October 2026•
1 min read

Viatris to Acquire Pacira BioSciences for $1.65 Billion to Expand Pain Therapy Portfolio

Two men shaking hands between Viatris and Pacira Biosciences buildings, with a large pill and $1.65B sign.

Key Facts

1Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash.
2The transaction has an aggregate equity value of approximately $1.65 billion and is expected to close by the end of 2026.
3The deal adds patent-protected medicines EXPAREL and ZILRETTA to Viatris' portfolio of non-opioid pain therapies.

Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash. PR Newswire reported that the transaction has an aggregate equity value of approximately $1.65 billion and is expected to close by the end of 2026. The deal adds patent-protected medicines EXPAREL and ZILRETTA to Viatris' portfolio of non-opioid pain therapies.

PCRX was trading at $36.30 on October 8, 2026, after rallying 44% to reach the offer level, prompting Needham to downgrade the stock from Buy to Hold. Pacira options saw significant bearish activity with volume reaching 2,702 contracts, 166.1 times the usual level, while VTRS closed at $17.49 on October 7, 2026.